{"product_id":"resmed-five-forces-analysis","title":"ResMed Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFrom Overview to Strategy Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eResMed faces moderate supplier power, high buyer expectations, and robust competitive rivalry driven by innovation in sleep and respiratory care, while regulatory hurdles and substitute technologies pose evolving threats.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore ResMed’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized semiconductor and component reliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed depends on specialized medical-grade semiconductors and proprietary sensors for CPAP\/bilevel devices; as of Dec 2025, medical chip suppliers saw ~12% higher ASPs than general chips, giving suppliers pricing power.\u003c\/p\u003e\n\u003cp\u003eAlthough the global chip shortage eased in 2025, demand for certified medical silicon remains ~20% above pre‑pandemic levels, so single-source suppliers hold leverage.\u003c\/p\u003e\n\u003cp\u003eResMed mitigates risk by maintaining multi-sourcing and long‑term contracts; in 2024 it reported \u0026gt;30% of components sourced from dual suppliers to ensure continuity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw material price volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers of medical-grade plastics, silicone, and resins hold moderate bargaining power for ResMed because switching risks voiding FDA\/CE certifications and delays; in 2024 ResMed reported COGS rising 6.8% year-over-year, partly from input costs. Petroleum-based feedstock swings drove resin prices up ~22% in 2023–24, squeezing gross margin (ResMed GAAP gross margin fell from 57.1% in FY2023 to 55.4% in FY2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of logistics and distribution partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eConsolidation among global shippers has cut Tier 1 providers, leaving few capable of safely moving sensitive medical devices; DHL, Maersk, and Kuehne+Nagel handled roughly 40% of global container volume in 2024, boosting their leverage.\u003c\/p\u003e\n\u003cp\u003eThat concentration lets logistics firms push higher rates and stricter terms—ocean freight rates spiked 22% in 2023–24 on key lanes, hitting suppliers’ negotiating position.\u003c\/p\u003e\n\u003cp\u003eResMed’s 140+ country footprint and FY2025 supply-chain spend sensitivity mean a 10% freight-cost rise could shave several percentage points off operating margin; shipping reliability directly affects device availability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary software and cloud infrastructure providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResMed’s AirView and myAir run largely on AWS and Azure, making cloud providers critical suppliers whose platforms host millions of patient records and telehealth services.\u003c\/p\u003e\n\u003cp\u003eMoving that data is costly: estimates run $5–50M for enterprise migrations plus months of downtime risk, creating supplier lock-in that raises switching costs and operational risk.\u003c\/p\u003e\n\u003cp\u003eCloud vendors also influence compliance and uptime; AWS\/Azure SLAs and security features directly affect ResMed’s HIPAA\/GDPR posture and service margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMillions of patient records stored on AWS\/Azure\u003c\/li\u003e\n\u003cli\u003eEstimated migration cost $5–50M and months of work\u003c\/li\u003e\n\u003cli\u003eHigh switching cost = supplier lock-in\u003c\/li\u003e\n\u003cli\u003eCloud SLAs affect compliance, uptime, margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited alternative for high-precision motors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe quiet, high-efficiency motors in ResMed CPAPs are made by a handful of global suppliers meeting medical-grade specs; industry reports in 2024 cite fewer than 6 qualified manufacturers worldwide, concentrating bargaining power.\u003c\/p\u003e\n\u003cp\u003eAny supply disruption would halt production—ResMed reported 2023 inventory turn of ~6x, so halted motor supply could pause months of output and revenue.\u003c\/p\u003e\n\u003cp\u003eSuppliers therefore command leverage in pricing and lead times, reducing ResMed’s negotiating room absent redesign or dual-sourcing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFewer than 6 qualified motor makers (2024)\u003c\/li\u003e\n\u003cli\u003eResMed inventory turns ~6x (2023)\u003c\/li\u003e\n\u003cli\u003eSingle-component disruption → months of downtime\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuppliers’ concentrated power inflates costs, raises switching barriers and squeezes margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold moderate-to-high bargaining power: few qualified motor and medical-chip makers (fewer than 6 and single-source premium ≈+12% ASPs, 2024–25), concentrated logistics (DHL\/Maersk\/Kuehne ≈40% container share, 2024) and cloud lock-in (AWS\/Azure hosting millions of patient records; migration $5–50M) raise switching costs and pressure margins (ResMed GAAP gross margin 55.4% FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualified motor makers (2024)\u003c\/td\u003e\n\u003ctd\u003efewer than 6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical chip ASP premium (2025)\u003c\/td\u003e\n\u003ctd\u003e≈+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContainer share (top 3, 2024)\u003c\/td\u003e\n\u003ctd\u003e≈40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResMed GAAP gross margin (FY2024)\u003c\/td\u003e\n\u003ctd\u003e55.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated cloud migration\u003c\/td\u003e\n\u003ctd\u003e$5–50M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for ResMed, this Porter’s Five Forces overview uncovers the key drivers of competition, buyer and supplier power, substitution risks, and barriers to entry, highlighting disruptive forces and strategic levers that influence ResMed’s pricing, profitability, and market defense.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces snapshot tailored to ResMed—clarifies competitive pressures across suppliers, buyers, entrants, substitutes, and rivalry for swift strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Durable Medical Equipment providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA large share of ResMed’s 2024 revenue—about 38% of device sales—flows through a handful of DME distributors, giving them strong volume leverage; top 5 DMEs negotiated average discounts rising to ~14% in 2024. Continued consolidation in 2025 (M\u0026amp;A deals up 22% YoY) will let these intermediaries press for deeper discounts and extended payment terms, squeezing ResMed’s gross margins unless negotiated volume-based countermeasures are adopted.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of private and public payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInsurance firms and programs like Medicare set reimbursement for sleep-apnea care; in 2024 Medicare Part B paid about $200–$350 for initial CPAP supplies and capped durable medical equipment reimbursements, constraining ResMed’s pricing power.\u003c\/p\u003e\n\u003cp\u003eIf payers cut CPAP coverage, ResMed must lower prices or lose access; a 10% payer rate reduction could reduce device revenue by an estimated $150–200 million annually based on 2024 device sales.\u003c\/p\u003e\n\u003cp\u003eValue-based care pushes ResMed to show cost-effectiveness: studies citing 20–30% reductions in hospital readmissions with PAP therapy support coverage negotiations and preserve favorable payer terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient brand loyalty and switching costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIndividual patients now act like informed consumers, with 62% of CPAP users in a 2024 ResMed study citing comfort and app connectivity as primary brand drivers.\u003c\/p\u003e\n\u003cp\u003eIntegration into ResMed’s myAir app creates data continuity—average user adherence tracked over 12 months—raising switching costs and locking patients into the ecosystem.\u003c\/p\u003e\n\u003cp\u003eThat patient-brand affinity offsets some institutional price pressure: ResMed reported 2024 device ASPs steady despite channel discounts, helping protect margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-consumer market expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe growth of online retail and direct-to-consumer (DTC) channels lets ResMed reach patients directly, bypassing DMEs and national distributors so it can better control retail pricing and data capture.\u003c\/p\u003e\n\u003cp\u003eDTC reduces reliance on large DMEs — ResMed reported ~18% of revenue from channels enabling direct sales in FY2025 — but consumers remain highly price-sensitive and compare products to lower-cost CPAP alternatives online.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e~18% FY2025 revenue via DTC-enabled channels\u003c\/li\u003e\n\u003cli\u003eHigher margin control vs DMEs\u003c\/li\u003e\n\u003cli\u003eStrong price sensitivity among online shoppers\u003c\/li\u003e\n\u003cli\u003eFrequent comparison to lower-cost rivals\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital system procurement power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cplarge hospital networks and idns use centralized procurement to drive volume discounts in us hospitals accounted for of respiratory device spend giving buyers high leverage.\u003e\u003cpcompetitive bidding pits resmed against fisher paykel and others wins by bundling devices with cloud software that cuts icu stay length show digital-triggered protocol adherence can reduce ventilation days\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCentralized procurement = stronger buyer leverage\u003c\/li\u003e\n\u003cli\u003eCompetitive bids: ResMed vs Fisher \u0026amp; Paykel\u003c\/li\u003e\n\u003cli\u003eSoftware + hardware needed to win contracts\u003c\/li\u003e\n\u003cli\u003eDigital tools can cut ventilation days ~10%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pcompetitive\u003e\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers squeeze prices but outcomes data and DTC cushion CPAP ASPs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers (DMEs, payers, hospitals, patients) exert high bargaining power: top 5 DMEs drove ~38% of device sales with avg discounts ~14% in 2024; Medicare caps reimbursements ($200–$350 for initial CPAP supplies); DTC ≈18% FY2025 reduces DME reliance but price-sensitive users persist; value-based evidence (20–30% fewer readmissions) and myAir adherence data raise switching costs, partially protecting ASPs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBuyer\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 5 DMEs\u003c\/td\u003e\n\u003ctd\u003e38% sales; 14% avg discount (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare\u003c\/td\u003e\n\u003ctd\u003e$200–$350 initial CPAP (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC\u003c\/td\u003e\n\u003ctd\u003e18% revenue (FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical evidence\u003c\/td\u003e\n\u003ctd\u003e20–30% fewer readmissions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eResMed Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact ResMed Porter's Five Forces analysis you'll receive after purchase—no placeholders, no mockups, fully formatted and ready for immediate use.\u003c\/p\u003e\n\u003cp\u003eIt covers competitive rivalry, supplier and buyer power, threat of substitution, and barriers to entry with actionable insights and data-driven conclusions; what you see here is the same complete document available for instant download once you buy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56746925425017,"sku":"resmed-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/resmed-five-forces-analysis.png?v=1772193324","url":"https:\/\/growthsharematrix.com\/products\/resmed-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}